News Daily News Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks Michael O'Riordan August 01, 2025
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for June 2025 Michael O'Riordan June 30, 2025
News Conference News SCAI 2025 When Early Cardiogenic Shock Isn’t Dealt With, Outcomes Can Suffer L.A. McKeown May 09, 2025
News Daily News ‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials Michael O'Riordan February 20, 2025
News Daily News Use of Secondary CVD Prevention Meds Still Meager Worldwide Caitlin E. Cox February 03, 2025
News Conference News AHA 2024 One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024 Shelley Wood November 14, 2024
News Conference News ACC 2024 Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI Shelley Wood April 06, 2024
News Daily News Most Takotsubo Patients Die From CV Causes, but Standard Meds No Help Todd Neale January 11, 2024
News Daily News Prescribing a Generic for CVD? Plan, Drug Type, and Condition Impact Availability Todd Neale September 13, 2023
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for November 2022 Caitlin E. Cox December 01, 2022
News Daily News Certain CV Meds Tied to Higher MI Risk in Warmer Weather Caitlin E. Cox August 04, 2022
News Daily News AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD Caitlin E. Cox December 28, 2021
News Conference News ESC 2020 Insights From a Deep Dive Into CV Risk Among Hospitalized COVID-19 Patients Shelley Wood September 04, 2020
News Daily News SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function Todd Neale July 02, 2018
News Daily News Meta-analysis Calls Into Question Strength of Guidance for RAS Blockade in Patients With Stable CAD Todd Neale January 19, 2017